Venous thromboembolism (VTE) risk assessment and prophylaxis, as currently practised and recommended, is often underutilized. Venous thrombosis is a major problem worldwide, and is often preventable in the hospitalized setting. It is estimated that approximately 100:100,000 persons have a first time VTE event per year. In fact, the incidence of VTE is identical to cardiovascular incidence for patients at moderate risk as shown by the recent Jupiter Trial. 1 Thus, at least 200,000 patients per year (as a low estimate) are affected by VTE. About 30% of patients with VTE suffer mortality at 30 days, and 30% have a recurrent VTE at 10 years follow-up. 2 This overview will focus on epidemiology, VTE risk assessment and quality measures, prophylaxis and the potential utility of biomarkers.
Risks and VTE impact
The cumulative risk for VTE is dependent on multiple factors (Table 1) . 3 First, the intrinsic thrombotic risk is mitigated by a small group of inherited risk factors including the deficiencies of natural anticoagulant proteins (e.g. antithrombin), genetic abnormalities such as factor V Leiden or prothrombin 20210A, and/or the other miscellaneous hypercoagulable states such as antiphospholipid antibody syndrome. More common are acquired risk factors such as increased age, prior VTE, presence of malignancy, obesity and use of certain medications such as oral contraceptives or hormone replacement therapy. More variable risk factors are indwelling catheters (including upper extremity catheters), inflammatory bowel disease and presence of varicose veins. Prothrombotic stress triggers include surgery, pregnancy, trauma and probably systemic infection. Together, these factors may culminate as a clinical VTE. Prevention of VTE is based on the inventory and knowledge of these risk factors at the patient level.
We assessed the impact of VTE occurrence on a large group of surgical patients using a hospital administrative discharge database. In brief, approximately 200,000 patients undergoing six common cardiovascular procedures were reviewed for a secondary diagnosis of VTE using ICD9-CM codes. 4 Overall, the rate of clinical VTE varied from 0.26% to 1.2% depending on the procedure. Carotid endarterectomy had the lowest and abdominal aortic aneurysm had the highest VTE incidence. The occurrence of VTE more than doubled the cost and length of stay, and was associated with a two-fold increased odds of death. In a more detailed analysis using the patient centred Veteran's Affairs National Surgical Quality Improvement database, 10 common operations were reviewed, encompassing 76,000 patients. Again, carotid endarterectomy had the lowest VTE incidence, while total hip arthroplasty had the highest at 1.34%. The occurrence of VTE increased the risk of death by 2.4-fold and was strongly associated with postoperative inflammatory states, including those of urinary tract infection, myocardial infarction and pneumonia; all increasing the VTE risk approximately two to nearly three-fold. 5 Malignancy is also a well-known risk factor for VTE. When patients with malignancy develop VTE, a significant decrease in survival is observed. Factors that increase VTE risk in cancer patients, based on a large cancer registry, include a solid as compared with haematological tumour, leucopaenia, infection and later stage of cancer. 6 Others have shown the site of cancer (gastrointestinal versus non-gastrointestinal), an elevated prechemotherapy platelet count and a low haemoglobin also independently increase the risk of VTE in those with malignancy. 7 In cancer patients who require surgery, location of primary tumour, presence of metastases, receipt of chemotherapy and presence of central venous access are all known to alter VTE risk. 8 Thus, stratification of the types of risks is important as not all variables confer the same overall VTE risk.
VTE as a quality indicator
Venous thrombosis and the sequelae are now a highprofile disease for which prevention is key ( Figure 1 ). The Federal Government has become focused on many processes related to quality of care. For example, the Agency for Healthcare Research and Quality ranked 90 variables for patient safety and quality of care, of which the foremost is appropriate use of VTE prophylaxis in patients at risk (www. psnet.ahrq.gov). The Centre for Medicare and Medicaid services considered listing VTE as a 'never event', for total knee and total hip arthroplasty in 2009 (www.cms.hhs.gov/). Furthermore, the Surgical Care Improvement Project (www.jointcommission. org/preformancemeasures) also includes assessment of DVT, specifically measuring the prophylaxis and risk assessments rates. Confirming the importance of VTE nationally is the recent call to action by the USA Surgeon General. 9 International survey data on at risk patients suggest that at least 50% of patients may not receive adequate prophylaxis, including both medical and surgical groups. 10 In some patients, contraindications to VTE prophylaxis may be present. However, the leading cause of inadequate VTE prophylaxis is likely medical professionals not performing risk assessment, and furthermore the risk level of the patient may not match the prescribed prophylaxis. Various VTE assessment models have been proposed. An ideal model would both identify an individual patient's VTE risk and recommend appropriate prophylaxis. This risk model would identify patients at highest and lowest VTE risk, be evidence based and be validated in a diverse patient population.
The American College of Chest Physicians (ACCP) guidelines suggests that group VTE prophylaxis is most appropriate, with low, moderate and high-risk patients categories as the best strategy. 11 Concerns with this approach include underor over-estimating the VTE risk, as well as not distinguishing the variables that contribute to the category classification. Additionally, the broad classification scheme makes formal validation difficult. In contrast to the ACCP group prophylaxis model, the Caprini Risk Assessment Model 12 creates an individualized risk assessment score based on the presence or absence of over 35 risk factors. The Caprini model's ability to predict VTE risk has been validated for general, urological and vascular surgery patients, 13 as well as those patients having postbariatric body contouring surgery. 14 We have adopted the Caprini Risk Assessment Model 12 and have integrated this tool into our electronic medical record. The utility of this individual risk assessment approach is supported by a retrospective study of 8216 patients between July 2001 and January of 2008 at the University of Michigan. 13 Using the Caprini risk factor scoring system, we found that those patients who had a score of 0-1 had 0% VTE incidence, while those with a score .8 had approximately 6.5% incidence of VTE at 30 days. The independent factors associated with increased VTE for the whole group included recent pregnancy, sepsis, malignancy, a history of VTE, as well as central venous access. From these data, we concluded that the Caprini score accurately reflects the anticipated 30-day clinical VTE incidence. This score, if very high, might further identify patients who are likely to benefit from extended out of hospital prophylaxis, and there might be a 'super high risk' category such that prophylactic full strength anticoagulation may be indicated. 15 VTE risk assessment represents an ongoing research endeavour. What remains unknown is the level of prophylaxis to provide for a specific risk score or categorization, in addition to the appropriate weighting of various risk factors when the risk score or categorization is generated. Further validation studies of existing risk assessment models are needed, including head-to-head comparisons between group risk categorization and individual risk assessment. Finally, studies that examine efficacy, safety and cost of prophylaxis regimens recommended by existing risk assessment models are required. These studies must be updated as new chemoprophylaxis agents are developed.
VTE prophylaxis options and ways to improve compliance
The currently recommended measures for VTE prophylaxis include pharmacological and mechanical. These measures aim to either decrease the thrombosis propensity by affecting the clotting system or improve venous haemodynamics by increasing the flow. Pharmacologic choices include low-dose unfractionated heparin 5000 units/thrice daily, low molecular weight heparin daily or twice daily, fondaparinux (anti-Xa inhibitor) daily, or a low-dose vitamin K antagonist (for the highest risk patients) ( Table 2) . 11 The risk of major bleeding on pharmacological prophylaxis is less than 3%. 16 A recent meta-analysis of bleeding complications in general surgery patients examined 33 studies in which chemoprophylaxis was provided. Haematoma requiring a second operation occurred in only 1% of patients. 17 Intermittent pneumatic compression placed on the lower limbs are only effective if actually on the patient and the device turned on. 18 Too many times, the intermittant pneumatic compression devices are actually treating the bedpost.
Chemoprophylaxis should be continued while the patient is non-ambulatory and in-active. With increasing usage of early discharge and broad use of home health care, consideration of postdischarge prophylaxis is important. Literature supports that postoperative orthopaedic, intra-abdominal and pelvic malignancy patients should receive prophylaxis for 30 days after their surgery. 11, 19 Recent results from the UK's Million Women Study demonstrate that VTE risk may remain substantially elevated for at least 90 days after surgery. 20 It is now recognized that a VTE is associated with an incident surgical or stress event if it occurs within 90 days of the procedure. 21, 22 Prophylaxis adherence can be improved via evidence-based guidelines that are actively implemented, as opposed to passively disseminated. The most effective processes are active reminders for the clinician to assess VTE risk, coupled with recommendations for appropriate prophylaxis. An example would be to distill the current ACCP guidelines as interactive reminders and ready information for clinicians. This includes an active audit and feedback system to the clinicians. 23 Computer alert systems seem to be most promising and coalesce with the advent of the electronic medical health record at many centres. A recent randomized controlled trial to issue alerts to physicians facilitated the detection of highrisk patients and increased the use of VTE prophylaxis from 14.5% to 33.5%. These interventions reduced VTE incidence by 41%. 21 
Biomarkers and VTE
At our institution, about 85-90% of all venous duplex scans for limb symptoms or DVT suspicion are negative studies. Biomarkers for VTE should improve the pretest probability to better 'rule in' a VTE diagnosis (Table 3) . While currently used in the outpatient setting, these need to be tested in the post-operative or hospital setting to detect those patients at high risk, potentially obviating an ultrasound scan. The most commonly used biomarker is D-dimer, which has an excellent sensitivity, but low specificity. Thus, D-dimer has a high certainty to rule out VTE. 24 D-dimer is also useful in determining if active thrombus metabolism is occurring and allow modification of VKA duration. Thrombin generation has been assayed in at-risk patients and allows prediction of recurrence risk but has not been studied for incident VTE diagnosis. 25 Another potentially newer biomarker to 'rule in' the diagnosis of VTE is P-selectin. P-selectin is a cell adhesion molecule, present in platelets, endothelium, as well as leukocytes. Strong experimental data suggest its role as a pathophysiological factor in DVT, and correlative studies are present in humans. 26, 27 Forthcoming data suggest that serum P-selectin levels are sensitive and specific for VTE, in contrast to D-dimer. Whether P-selectin levels are associated with VTE in surgical patients is as of yet unclear, but studies are ongoing.
Conclusion
Hospitals and physicians currently possess all the tools required to appropriately risk-stratify patients for VTE, provide adequate prophylaxis and systematically decrease VTE occurrence in hospitalized patients. New biomarkers may better assist with VTE risk assessment and early detection (despite prophylaxis). Ongoing refinements of existing riskstratification tools, including risk factor identification and weighting, will further determine appropriate levels and duration of prophylaxis. Finally, VTE risk is dynamic during a patient's hospital course, and prophylaxis requirements must be regularly re-evaluated and modified as clinical circumstances change. 
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